Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids
Patients often see a cytokine normalization, and symptom relief - backed by before-and-after labs
Remarkably, saliva methylation profiles associate with intestinal patterns, supporting their potential as non-invasive biomarkers (150)
The Overlap Risk: Why Concurrent Use Is Not Recommended The Pharmaceutical Journal (Royal Pharmaceutical Society, December 2025) states that concurrent administration of tirzepatide and semaglutide "could heighten side effects" due to their "overlapping incretin activity." When both drugs are active simultaneously, the GLP-1 receptor faces amplified agonist load
A body composition substudy of the Phase 2 diabetes trial, published in The Lancet Diabetes & Endocrinology in 2025, used DXA scans to measure changes in fat and lean mass in 189 participants
